Estimates for baseline prognosis and 5-year outcomes
Five-year baseline prognosis (chance of being alive without recurrent cancer if no adjuvant therapy is given) based on ulceration, number of nodes, tumor depth and nodal bulk.
Five-year baseline prognosis with surgery alone:
Five-year prognosis with adjuvant Interferon:
Adjuvant interferon therapy was associated with a hazard ratio of 0.7 (i.e., a 30 percent overall reduction of the risk) for overall and disease-free survival based on a recent pooled analysis of trials with a high-dose interferon arm. This estimate was used for the calculations above.
*Based on estimated proportional benefits in patients with involved lymph nodes.
The rationale for development of, and details regarding, this tool are provided in the study "Improving the Understanding of Adjuvant Therapy Benefits for Colon Cancer: A Prognostic Tool Developed From a Pooled Analysis" presented at the 2003 annual session of the American Society of Clinical Oncology (ASCO).